Becton Dickinson and Company Limited

Other

Becton Dickinson Research Center

Philip G Green

Burton H Sage

Carl Randolph Bock

Arnold J Repta

Munir A Hussain

Bernt Fredrik Broberg

Ronald J Clark

This invention relates to novel methods and devices for iontophoretically administering therapeutic doses of cell adhesion receptor antagonists in a controlled manner through the skin. Such antagonist compounds include but are not limited to antagonists of the IIb/IIIa and .alpha..sub.v .beta..sub.3 integrins and related cell surface adhesive protein receptors. The present invention includes iontophoretic delivery devices comprising cell adhesion receptor antagonists. Such methods and devices are useful, alone or in combination with other therapeutic agents, for the treatment of thromboembolic disorders, angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.

Iontophoretic delivery of cell adhesion inhibitors

This invention relates to novel methods and devices for iontophoretically administering therapeutic doses of cell adhesion receptor antagonists in a controlled manner through the skin. Such antagonist compounds include but are not limited to antagonists of the IIb/IIIa and .alpha..sub.v .beta..sub.3 inter and related cell surface adhesive protein receptors. The present invention includes iontophoretic delivery devices comprising cell adhesion receptor antagonists. Such methods and devices are useful, alone or in combination with other therapeutic agents, for the treatment of thromboembolic disorders, angiogenic disorders, inflammation, bone degradation, cancer metastasis, diabetic retinopathy, restenosis, macular degeneration, and other conditions mediated by cell adhesion and/or cell migration and/or angiogenesis.

The present invention relates to a method and device for the iontophoretic delivery of a therapeutic dose range of bisphosphonate to be delivered to a patient over a period of lime to prevent the onset for advancement of osteoporosis and other metabolic bone diseases for a selected period of time.

Device for the iontophoretic administration of bisphosphonates

A method for preventing the onset or advancement of osteoporosis or other metabolic bone disorders in a patient by iontophoretically administering to the patient an effective amount of a bisphosphonate which would be effective for preventing the onset or advancement of osteoporosis or other bone disorders and wherein the effective amount of bisphosphonate is delivered over a period of from about four (4) hours to about forty-eight (48) hours, at intervals of from about once a week to about twice a year and wherein the effective amount of bisphosphonate also contains an agent capable of chelating calcium.

Method for the iontophoretic administration of bisphosphonates

A method for forming and packaging an iontophoretic patch in an inert atmosphere to provide increased shelf-life. The method includes a number of sub-assemblies for forming a well in a laminate material, forming the reservoir and dosing the reservoir, sealing the laminate material and another laminate material together to form a continuous web from which the individual patches are cut. In addition, the patch can be subsequently enclosed in an individual package. In this way, the patch and/or package provides a commercially suitable shelf-life to the drug-filled patch stored therein.

Growing community of inventors

Cliffside Park, NJ, United States of America

Philip G Green